瑞典全国登记研究:抗TNF药物与维得利珠单抗作为IBD二线生物制剂的药物生存对比
基于瑞典全国登记数据,纳入2014-2016年启动二线生物治疗的1363例IBD患者,经倾向评分匹配后分析400例。克罗恩病中抗TNF与维得利珠单抗12个月药物生存率相似(74% vs 73%),溃疡性结肠炎中亦无显著差异(62% vs 69%),但维得利珠单抗组无IBD相关住院生存率较低(82% vs 93%,P=0.02)。
要点
- 二线抗TNF与维得利珠单抗在IBD中12个月药物生存率总体相似。
- 溃疡性结肠炎中维得利珠单抗组无IBD相关住院生存率低于抗TNF组。
- 克罗恩病中两组各项次要结局均无统计学显著差异。
核心结论
- 基于瑞典临床实践,二线抗TNF药物与维得利珠单抗在12个月时的有效性和安全性大体相似。
研究设计与样本
- 利用瑞典全国登记数据构建倾向评分匹配队列,纳入2014-2016年启动二线抗TNF或维得利珠单抗的克罗恩病或溃疡性结肠炎患者1363例。
- 经1:1倾向评分匹配后,400例患者纳入分析(克罗恩病198例,溃疡性结肠炎202例)。
主要发现
- 克罗恩病中,维得利珠单抗组与抗TNF组的12个月药物生存率分别为73%和74%(差异1个百分点,95%CI -11至13,P=0.87)。
- 溃疡性结肠炎中,维得利珠单抗组与抗TNF组的12个月药物生存率分别为69%和62%(差异-7个百分点,95%CI -20至6,P=0.30)。
- 溃疡性结肠炎中,维得利珠单抗组无IBD相关住院生存率为82%,抗TNF组为93%(P=0.02)。
- 克罗恩病中,无IBD相关住院、手术、抗生素使用、感染住院及皮质类固醇暴露的生存率在两组间均无统计学显著差异。
- 溃疡性结肠炎中,无结肠切除术、抗生素使用、感染住院及皮质类固醇暴露的生存率在两组间均无统计学显著差异。
临床怎么用
- 在二线生物制剂选择时,抗TNF药物与维得利珠单抗的12个月药物生存率总体相当,可结合患者具体情况个体化决策。
- 对于溃疡性结肠炎患者,需注意维得利珠单抗组无IBD相关住院生存率较低,但解读时应考虑研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comparisons of second-line anti-tumour necrosis factor (TNF) agents and vedolizumab are sparse. AIM: To evaluate the effectiveness of anti-TNF agents compared to vedolizumab as second-line biologics in inflammatory bowel disease (IBD). METHODS: A propensity score-matched cohort was created using Swedish nationwide registers. Patients with Crohn's disease or ulcerative colitis, exposed to first-line anti-TNF treatment, who initiated a second anti-TNF agent or vedolizumab in 2014-2016 (N = 1363) were included. The primary outcome was drug survival at 12 months. Secondarily, we assessed survival without IBD-related hospitalisation, IBD-related surgery, antibiotics, or hospitalisation because of infection, and also corticosteroid exposure. RESULTS: After 1:1 propensity score matching, 400 patients (Crohn's disease, N = 198; ulcerative colitis, N = 202) remained. For Crohn's disease, drug survival was 73% in the vedolizumab group vs 74% in the anti-TNF group (difference: 1 percentage point; 95% confidence interval [CI]:-11-13; P = 0.87). Survival without IBD-related hospitalisation (82% vs 88%), surgery (82% vs 89%), antibiotics (65% vs 71%), hospitalisation due to infection (95% vs 88%) and corticosteroids (58% vs 48%) were not statistically significantly different between groups. For ulcerative colitis, drug survival was 69% in the vedolizumab group vs 62% in the anti-TNF group (difference: -7 percentage points; 95% CI: -20 to 6; P = 0.30). Vedolizumab-treated patients had lower survival without IBD-related hospitalisation (82% vs 93%, P = 0.02). Survival without colectomy (93% vs 97%), antibiotics (81% vs 70%), hospitalisation due to infection (92% vs 92%) and corticosteroids (58% vs 48%) were not statistically significantly different. CONCLUSIONS: Based on Swedish clinical practice, the effectiveness and safety of second-line anti-TNF and vedolizumab at 12 months appeared largely similar.
引用
- Rundquist S, Sachs MC, Eriksson C, et al. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Aliment Pharmacol Ther. 2020. PMID: 33340426. doi:10.1111/apt.16193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。